{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:41:34Z","timestamp":1790905294866,"version":"4.1.0"},"reference-count":75,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Victor Babe\u0219 University of Medicine and Pharmacy"},{"id":[{"id":"https:\/\/ror.org\/00afdp487","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background\/Objectives: BPC-157 (body protection compound 157) is a synthetic pentadecapeptide derived from a gastric protein fragment with reported cytoprotective and regenerative properties across multiple organ systems. Despite over three decades of preclinical research demonstrating consistent biological activity, its pharmaceutical development remains rudimentary, with no approved formulation, no validated dosing regimen, and no completed Phase II clinical trial. This review critically evaluates BPC-157 from a biopharmaceutical and drug development perspective, examining its physicochemical and pharmacokinetic properties, formulation challenges across routes of administration, the pharmacokinetic\u2013pharmacodynamic disconnect that characterizes its preclinical profile, and the regulatory and translational barriers that currently preclude clinical advancement. Methods: A narrative review of the literature was conducted using PubMed\/MEDLINE, Embase, and Cochrane Library from database inception to April 2026. Search terms included \u201cBPC-157\u201d, \u201cBPC157\u201d, \u201cbody protection compound 157\u201d, \u201cpentadecapeptide\u201d, and \u201cGEPPPGKPADDAGLV\u201d, each combined with \u201cpharmacokinetics\u201d, \u201cformulation\u201d, \u201cbiopharmaceutics\u201d, \u201cdrug delivery\u201d, \u201cclinical trial\u201d, \u201ctoxicology\u201d, and \u201cregulatory\u201d. Patent databases (Espacenet, Google Patents) and regulatory agency websites (FDA, EMA, WADA) were searched independently. Searches were supplemented by forward and backward citation tracking of key references. Articles were selected based on relevance to biopharmaceutical characterization, pharmacokinetics, formulation science, clinical evidence, and regulatory status; pharmacodynamic studies were included insofar as they inform translational development. Evidence was synthesized with emphasis on pharmaceutical characterization, formulation science, and translational feasibility; no formal quality assessment instrument was applied, consistent with the narrative review design. Results: BPC-157 exhibits unusual stability in gastric juice and demonstrates activity via oral, parenteral, and topical routes, yet its human pharmacokinetic profile remains critically undercharacterized despite a recently published formal preclinical ADME study in two species confirming a sub-30-min plasma half-life, linear dose-proportional kinetics, and intramuscular bioavailability of 14\u201351% depending on species. A plasma half-life of under 30 min\u2014confirmed preclinically and in a preliminary two-subject human pilot\u2014contrasts with prolonged biological effects lasting hours to days\u2014a disconnect with significant implications for dosing strategy and formulation design. No pharmaceutical-grade formulation has been developed or validated. The peptide lacks bcs classification data, permeability characterization, and formal excipient compatibility studies. Available clinical data derive from fewer than 30 subjects across three uncontrolled pilot studies, none of which employed standardized pharmaceutical preparations. Conclusions: BPC-157 presents a compelling but pharmaceutically underdeveloped profile. The primary barrier to clinical translation is not the absence of biological activity, but the absence of fundamental pharmaceutical science: characterized formulations, validated pharmacokinetics, and a coherent drug development strategy. Addressing these biopharmaceutical gaps is a prerequisite for any meaningful clinical program.<\/jats:p>","DOI":"10.3390\/pharmaceutics18050625","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:39:34Z","timestamp":1779295174000},"page":"625","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4951-1702","authenticated-orcid":false,"given":"Diana-Maria","family":"Mateescu","sequence":"first","affiliation":[{"name":"Department of General Medicine, Doctoral School, \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragos-Mihai","family":"Gavrilescu","sequence":"additional","affiliation":[{"name":"Department of Orthodontics, Dental District, Z\u0103gazului 3, One Floreasca Vista, Sector 1, 014261 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florin Eugen","family":"Constantinescu","sequence":"additional","affiliation":[{"name":"Department of Prosthodontics, Faculty of Dental Medicine, Carol Davila University of Medicine and Pharmacy, Eroii Sanitari Blvd 8, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Oancea","sequence":"additional","affiliation":[{"name":"Pulmonology Department, \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian-Cosmin","family":"Ilie","sequence":"additional","affiliation":[{"name":"Department of Public Health and Sanitary Management, \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania"},{"name":"Centre for Translational Research and Systems Medicine, Faculty of Medicine, \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, Eftimie Murgu Sq. No. 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Folescu","sequence":"additional","affiliation":[{"name":"Department of Balneology, Medical Recovery and Rheumatology, Family Discipline, Center for Preventive Medicine, \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7487-4639","authenticated-orcid":false,"given":"Mihaela-Diana","family":"Popa","sequence":"additional","affiliation":[{"name":"Department of Microbiology, \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3536-6099","authenticated-orcid":false,"given":"Stela","family":"Iurciuc","sequence":"additional","affiliation":[{"name":"Cardiology Department, \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3896-9599","authenticated-orcid":false,"given":"Camelia-Oana","family":"Muresan","sequence":"additional","affiliation":[{"name":"Legal Medicine, Timisoara Institute of Legal Medicine, 300041 Timisoara, Romania"},{"name":"Ethics and Human Identification Research Center, \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania"},{"name":"Discipline of Forensic Medicine, Bioethics, Deontology, and Medical Law, Department of Neuroscience, \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Enache","sequence":"additional","affiliation":[{"name":"Legal Medicine, Timisoara Institute of Legal Medicine, 300041 Timisoara, Romania"},{"name":"Ethics and Human Identification Research Center, \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania"},{"name":"Discipline of Forensic Medicine, Bioethics, Deontology, and Medical Law, Department of Neuroscience, \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"J\u00f3zwiak, M., Bauer, M., Kamysz, W., and Kleczkowska, P. (2025). Multifunctionality and Possible Medical Application of the BPC 157 Peptide\u2014Literature and Patent Review. Pharmaceuticals, 18.","DOI":"10.3390\/ph18020185"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Sikiric, P., Boban Blagaic, A., Strbe, S., Beketic Oreskovic, L., Oreskovic, I., Sikiric, S., Staresinic, M., Sever, M., Kokot, A., and Jurjevic, I. (2024). The Stable Gastric Pentadecapeptide BPC 157: Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals, 17.","DOI":"10.3390\/ph17040461"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41573-019-0053-0","article-title":"Advances in Oral Peptide Therapeutics","volume":"19","author":"Drucker","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Kralj, T., Kokot, A., Zlatar, M., Masnec, S., Kasnik Kovac, K., Milkovic Perisa, M., Batelja Vuletic, L., Giljanovic, A., Strbe, S., and Sikiric, S. (2022). Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma. Biomedicines, 10.","DOI":"10.3390\/biomedicines10010089"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Sikiric, P., Seiwerth, S., Skrtic, A., Staresinic, M., Strbe, S., Vuksic, A., Sikiric, S., Bekic, D., Soldo, D., and Grizelj, B. (2023). Stable Gastric Pentadecapeptide BPC 157\u2014Possible Novel Therapy of Glaucoma and Other Ocular Conditions. Pharmaceuticals, 16.","DOI":"10.3390\/ph16071052"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.4155\/tde.13.104","article-title":"Basics and Recent Advances in Peptide and Protein Drug Delivery","volume":"4","author":"Bruno","year":"2013","journal-title":"Ther. Deliv."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/15563316251355551","article-title":"Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review","volume":"21","author":"Vasireddi","year":"2025","journal-title":"HSS J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nchem.1062","article-title":"Contemporary Strategies for Peptide Macrocyclization","volume":"3","author":"White","year":"2011","journal-title":"Nat. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide Therapeutics: Current Status and Future Directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov. Today"},{"key":"ref_10","first-page":"20","article-title":"Safety of Intravenous Infusion of BPC-157 in Humans: A Pilot Study","volume":"31","author":"Lee","year":"2025","journal-title":"Altern. Ther. Health Med."},{"key":"ref_11","unstructured":"U.S. Food and Drug Administration (2026, April 17). 503A Categories Update: Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, Available online: https:\/\/www.fda.gov\/media\/94155\/download."},{"key":"ref_12","unstructured":"World Anti-Doping Agency (2026, April 17). The 2026 Prohibited List. Available online: https:\/\/www.wada-ama.org\/en\/prohibited-list."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41573-020-00135-8","article-title":"Trends in Peptide Drug Discovery","volume":"20","author":"Muttenthaler","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Zheng, B., Wang, X., Guo, M., and Tzeng, C.-M. (2025). Therapeutic Peptides: Recent Advances in Discovery, Development, and Clinical Applications. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26115131"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Chen, G. (2025). Advances in the Oral Delivery of Protein and Peptide Drugs. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17050616"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.euprot.2014.05.003","article-title":"The Emergence of Peptides in the Pharmaceutical Business","volume":"4","author":"Uhlig","year":"2014","journal-title":"EuPA Open Proteom."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1208\/s12248-014-9687-3","article-title":"Strategic Approaches to Optimizing Peptide ADME Properties","volume":"17","author":"Di","year":"2015","journal-title":"AAPS J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s40262-013-0079-0","article-title":"Pharmacokinetics and Pharmacokinetic\u2013Pharmacodynamic Correlations of Therapeutic Peptides","volume":"52","author":"Diao","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Baral, K.C., and Choi, K.Y. (2025). Barriers and Strategies for Oral Peptide and Protein Therapeutics Delivery: Update on Clinical Advances. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17040397"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.drudis.2009.10.009","article-title":"Synthetic Therapeutic Peptides: Science and Market","volume":"15","author":"Vlieghe","year":"2010","journal-title":"Drug Discov. Today"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"He, L., Feng, D., Guo, H., Zhou, Y., Li, Z., Zhang, K., Zhang, W., Wang, S., Wang, Z., and Hao, Q. (2022). Pharmacokinetics, Distribution, Metabolism, and Excretion of Body-Protective Compound 157, a Potential Drug for Treating Various Wounds, in Rats and Dogs. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1026182"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The Biology of VEGF and Its Receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrm1911","article-title":"VEGF Receptor Signalling\u2014In Control of Vascular Function","volume":"7","author":"Olsson","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"265sr6","DOI":"10.1126\/scitranslmed.3009337","article-title":"Wound Repair and Regeneration: Mechanisms, Signaling, and Translation","volume":"6","author":"Eming","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nature07039","article-title":"Wound Repair and Regeneration","volume":"453","author":"Gurtner","year":"2008","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41392-024-01764-w","article-title":"TGF-\u03b2 Signaling in Health, Disease, and Therapeutics","volume":"9","author":"Deng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Bakalenko, N., Kuznetsova, E., and Malashicheva, A. (2024). The Complex Interplay of TGF-\u03b2 and Notch Signaling in the Pathogenesis of Fibrosis. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms251910803"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/eurheartj\/ehr304","article-title":"Nitric Oxide Synthases: Regulation and Function","volume":"33","author":"Sessa","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1152\/physrev.00011.2005","article-title":"Heme Oxygenase-1\/Carbon Monoxide: From Basic Science to Therapeutic Applications","volume":"86","author":"Ryter","year":"2006","journal-title":"Physiol. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrd4623","article-title":"Strategies to Increase Nitric Oxide Signalling in Cardiovascular Disease","volume":"14","author":"Lundberg","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1039\/D1TB00847A","article-title":"Recent Advances in the Development of Nitric Oxide-Releasing Biomaterials and their application potentials in Wound Healing","volume":"9","author":"Wu","year":"2021","journal-title":"J. Mater. Chem. B"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nature07201","article-title":"Origin and Physiological Roles of Inflammation","volume":"454","author":"Medzhitov","year":"2008","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"a001651","DOI":"10.1101\/cshperspect.a001651","article-title":"The Nuclear Factor NF-\u03baB Pathway in Inflammation","volume":"1","author":"Lawrence","year":"2009","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.immuni.2016.02.015","article-title":"Macrophages in Tissue Repair, Regeneration, and Fibrosis","volume":"44","author":"Wynn","year":"2016","journal-title":"Immunity"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Gojkovic, S., Krezic, I., Vranes, H., Zizek, H., Drmic, D., Batelja Vuletic, L., Milavic, M., Sikiric, S., Stilinovic, I., and Simeon, P. (2021). Robert\u2019s Intragastric Alcohol-Induced Gastric Lesion Model as an Escalated General Peripheral and Central Syndrome, Counteracted by the Stable Gastric Pentadecapeptide BPC 157. Biomedicines, 9.","DOI":"10.3390\/biomedicines9101300"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Rasic, D., Zenko Sever, A., Rasic, F., Strbe, S., Rasic, Z., Djuzel, A., Duplancic, B., Boban Blagaic, A., Skrtic, A., and Seiwerth, S. (2021). Stable Gastric Pentadecapeptide BPC 157 Heals Established Vesicovaginal Fistula and Counteracts Stone Formation in Rats. Biomedicines, 9.","DOI":"10.3390\/biomedicines9091206"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Madzarac, G., Becejac, T., Penovic, T., Drazenovic, D., Kralj, L., Popovic Dolic, M., Sikiric, S., Beketic Oreskovic, L., Oreskovic, I., and Strbe, S. (2026). Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System\u2014Triple NO-Agent Approach in Rats. Pharmaceuticals, 19.","DOI":"10.3390\/ph19010145"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Zemba Cilic, A., Zemba, M., Cilic, M., Strbe, S., Ilic, S., Vukojevic, J., Zoricic, Z., Filipcic, I., Kokot, A., and Smoday, I.M. (2022). BPC 157, L-NAME, L-Arginine, NO-Relation, in the Suited Rat Ketamine Models Resembling \u201cNegative-like\u201d Symptoms of Schizophrenia. Biomedicines, 10.","DOI":"10.3390\/biomedicines10071462"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.2174\/1381612825666190206105232","article-title":"Recent Advances in Half-Life Extension Strategies for Therapeutic Peptides and Proteins","volume":"24","author":"Tan","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cbpa.2017.02.006","article-title":"Cyclic Peptide Therapeutics: Past, Present and Future","volume":"38","author":"Zorzi","year":"2017","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nm0603-653","article-title":"Angiogenesis in Health and Disease","volume":"9","author":"Carmeliet","year":"2003","journal-title":"Nat. Med."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"de la Torre, B.G., and Albericio, F. (2021). The Pharmaceutical Industry in 2020: An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules, 26.","DOI":"10.3390\/molecules26030627"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","article-title":"Therapeutic Peptides: Historical Perspectives, Current Development Trends, and Future Directions","volume":"26","author":"Lau","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/cbdd.12055","article-title":"The Future of Peptide-Based Drugs","volume":"81","author":"Craik","year":"2013","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jconrel.2019.02.016","article-title":"Current Strategies in Extending Half-Lives of Therapeutic Proteins","volume":"301","author":"Zaman","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Bajramagic, S., Sever, M., Rasic, F., Staresinic, M., Skrtic, A., Beketic Oreskovic, L., Oreskovic, I., Strbe, S., Loga Zec, S., and Hrabar, J. (2024). Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats\u2014A Review. Pharmaceuticals, 17.","DOI":"10.3390\/ph17081081"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Sikiric, P., Seiwerth, S., Skrtic, A., Staresinic, M., Strbe, S., Vuksic, A., Sikiric, S., Bekic, D., Soldo, D., and Grizelj, B. (2026). Fourier Transform Infrared Spectroscopic Characterization of Aortic Wall Remodeling by Stable Gastric Pentadecapeptide BPC 157 After Unilateral Adrenalectomy in Rats. Pharmaceuticals, 19.","DOI":"10.3390\/ph19010191"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Demirta\u0219, H., \u00d6zer, A., Y\u0131ld\u0131r\u0131m, A.K., Dursun, A.D., Sezen, \u015e.C., and Arslan, M. (2025). Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia-Reperfusion Injury. Medicina, 61.","DOI":"10.3390\/medicina61020291"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Matek, D., Matek, I., Staresinic, E., Japjec, M., Bojanic, I., Boban Blagaic, A., Beketic Oreskovic, L., Oreskovic, I., Ziger, T., and Novinscak, T. (2025). Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17010119"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Matek, D., Matek, I., Japjec, M., Matek, M., Prenc, J., Staresinic, B., Staresinic, E., Prtoric, A., Sikiric, S., and Beketic Oreskovic, L. (2026). Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157\u2014A Review. Pharmaceuticals, 19.","DOI":"10.3390\/ph19020309"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/ibd.20873","article-title":"Depression and anxiety in inflammatory bowel disease: A review of comorbidity and management","volume":"15","author":"Graff","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_52","first-page":"12","article-title":"Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study","volume":"30","author":"Lee","year":"2024","journal-title":"Altern. Ther. Health Med."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Knezevic, M., Gojkovic, S., Krezic, I., Zizek, H., Vranes, H., Malekinusic, D., Vrdoljak, B., Knezevic, T., Pavlov, K.H., and Drmic, D. (2021). Complex Syndrome of the Complete Occlusion of the End of the Superior Mesenteric Vein, Opposed with the Stable Gastric Pentadecapeptide BPC 157 in Rats. Biomedicines, 9.","DOI":"10.3390\/biomedicines9081029"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Sikiric, P., Seiwerth, S., Skrtic, A., Staresinic, M., Strbe, S., Vuksic, A., Sikiric, S., Bekic, D., Soldo, D., and Grizelj, B. (2025). BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide\u2019s Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on J\u00f3zwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide\u2014Literature and Patent Review. Pharmaceuticals, 18.","DOI":"10.3390\/ph18101450"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Staresinic, M., Japjec, M., Vranes, H., Prtoric, A., Zizek, H., Krezic, I., Gojkovic, S., Smoday, I.M., Oroz, K., and Staresinic, E. (2022). Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle. Biomedicines, 10.","DOI":"10.3390\/biomedicines10123221"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1161\/CIRCRESAHA.114.303819","article-title":"Reproducibility in Science: Improving the Standard for Basic and Preclinical Research","volume":"116","author":"Begley","year":"2015","journal-title":"Circ. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nature11556","article-title":"A Call for Transparent Reporting to Optimize the Predictive Value of Preclinical Research","volume":"490","author":"Landis","year":"2012","journal-title":"Nature"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1056\/NEJMra071667","article-title":"Myocardial Reperfusion Injury","volume":"357","author":"Yellon","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1172\/JCI62874","article-title":"Myocardial Ischemia-Reperfusion Injury: A Neglected Therapeutic Target","volume":"123","author":"Hausenloy","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMra1102942","article-title":"Ulcerative Colitis","volume":"365","author":"Danese","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative Colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"J\u00f3zwiak, M., Bauer, M., Kamysz, W., and Kleczkowska, P. (2025). Reply to Sikiric et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide\u2019s Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Pharmaceuticals, 18.","DOI":"10.3390\/ph18101451"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Sikiric, P., Seiwerth, S., Skrtic, A., Staresinic, M., Strbe, S., Vuksic, A., Sikiric, S., Bekic, D., Soldo, D., and Grizelj, B. (2025). Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System. Pharmaceuticals, 18.","DOI":"10.3390\/ph18060928"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Sikiric, P., Seiwerth, S., Rucman, R., Turkovic, B., Rokotov, D.S., Brcic, L., Sever, M., Klicek, R., Radic, B., and Drmic, D. (2023). Stable Gastric Pentadecapeptide BPC 157 May Recover Brain-Gut Axis and Gut-Brain Axis Function. Pharmaceuticals, 16.","DOI":"10.3390\/ph16050676"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1136\/gut.2010.218271","article-title":"Randomised Placebo-Controlled Trial of Teduglutide in Reducing Parenteral Nutrition and\/or Intravenous Fluid Requirements in Patients with Short Bowel Syndrome","volume":"60","author":"Jeppesen","year":"2011","journal-title":"Gut"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Yuan, C., Demers, A., Silva-Ortiz, V., Hasoon, J.J., Lee, W., Dave, K., Amirdelfan, K., Burke, H.W., Christo, P.J., and Robinson, C.L. (2026). From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27062876"},{"key":"ref_67","first-page":"1074","article-title":"Biologic Approaches to Cartilage Repair","volume":"37","author":"Rodeo","year":"2019","journal-title":"J. Orthop. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"399","DOI":"10.59249\/TKNM3388","article-title":"Local and Systemic Peptide Therapies for Soft Tissue Regeneration: A Narrative Review","volume":"97","author":"Cushman","year":"2024","journal-title":"Yale J. Biol. Med."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Barisic, I., Balenovic, D., Udovicic, M., Malekinusic, D., Zizek, H., Orct, T., Krezic, I., Gojkovic, S., Drmic, D., and Knezevic, M. (2022). Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020265"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Udovicic, M., Sever, M., Kavur, L., Loncaric, K., Barisic, I., Balenovic, D., Zivanovic Posilovic, G., Strinic, D., Uzun, S., and Batelja Vuletic, L. (2021). Stable Gastric Pentadecapeptide BPC 157 Therapy for Monocrotaline-Induced Pulmonary Hypertension in Rats Leads to Prevention and Reversal. Biomedicines, 9.","DOI":"10.3390\/biomedicines9070822"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Knezevic, M., Gojkovic, S., Krezic, I., Zizek, H., Malekinusic, D., Vrdoljak, B., Vranes, H., Knezevic, T., Barisic, I., and Horvat Pavlov, K. (2021). Occlusion of the Superior Mesenteric Artery in Rats Reversed by Collateral Pathways Activation: Gastric Pentadecapeptide BPC 157 Therapy Counteracts Multiple Organ Dysfunction Syndrome; Intracranial, Portal and Caval Hypertension; and Aortal Hypotension. Biomedicines, 9.","DOI":"10.3390\/biomedicines9060609"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Knezevic, M., Gojkovic, S., Krezic, I., Zizek, H., Malekinusic, D., Vrdoljak, B., Knezevic, T., Vranes, H., Drmic, D., and Staroveski, M. (2021). Occluded Superior Mesenteric Artery and Vein. Therapy with the Stable Gastric Pentadecapeptide BPC 157. Biomedicines, 9.","DOI":"10.3390\/biomedicines9070792"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Sikiric, P., Seiwerth, S., Skrtic, A., Staresinic, M., Strbe, S., Vuksic, A., Sikiric, S., Bekic, D., Soldo, D., and Grizelj, B. (2026). Conventional Antiarrhythmics Class I\u2013IV, Late INa Inhibitors, IKs Enhancers, RyR2 Stabilizers, Gap Junction Modulators, Atrial-Selective Antiarrhythmics, and Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Therapy in Arrhythmias. Pharmaceuticals, 19.","DOI":"10.3390\/ph19020235"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Sikiric, P., Seiwerth, S., Skrtic, A., Staresinic, M., Strbe, S., Vuksic, A., Sikiric, S., Bekic, D., Soldo, D., and Grizelj, B. (2026). Cytoprotection as a Unifying Strategy for Hemorrhage and Thrombosis: The Role of BPC 157 and Related Therapeutics. Pharmaceuticals, 19.","DOI":"10.3390\/ph19030463"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Sikiric, P., Udovicic, M., Barisic, I., Balenovic, D., Zivanovic Posilovic, G., Strinic, D., Uzun, S., Sikiric, S., Krezic, I., and Zizek, H. (2022). Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Peptide Therapy in Heart Disturbances, Myocardial Infarction, Heart Failure, Pulmonary Hypertension, Arrhythmias, and Thrombosis Presentation. Biomedicines, 10.","DOI":"10.3390\/biomedicines10112696"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/5\/625\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:43:54Z","timestamp":1779295434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/5\/625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":75,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["pharmaceutics18050625"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18050625","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]}}}